{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-166540","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.368783+00:00","generated_at":"2026-06-14T01:36:53.305718+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IO Biotech hits 225-patient enrollment milestone in Phase 3 melanoma trial; expanded to 380","bullets":["225 patients randomized in Phase 3 trial of IO102-IO103 + pembrolizumab for advanced melanoma.","Interim ORR analysis now triggered; positive data could enable BLA for accelerated approval in U.S.","Trial enrollment increased to 380 patients to potentially accelerate primary PFS endpoint.","Company expects full enrollment by year-end 2023; cash runway through Q3 2024.","CEO notes potential first vaccine approval in 2025 if interim analysis is positive."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-166540","json":"https://secwatch.observer/filing/0001193125-23-166540.json","markdown":"https://secwatch.observer/filing/0001193125-23-166540.md","text":"https://secwatch.observer/filing/0001193125-23-166540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523166540/0001193125-23-166540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523166540/d481906d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:36:53.305718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}